ArticleEuropean heart journal2021
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.
Article in European heart journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06543173 (Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator), which is not on this map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator (PRIMARY PREVENT-VT TRIAL)
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts.European heart journal · 2024Pooled it
- Trial
- Magnetocardiographic Rotation Score and Arrhythmic Endpoints in Primary-Prevention ICD Recipients: An Exploratory Substudy of the Magneto-SCD Trial.Journal of clinical medicine · 2026Article
- The role of comorbidities on periprocedural complications and outcomes in patients with defibrillators and cardiac resynchronization therapy: insights from the German device registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Impact of sex on the utilization of defibrillation-capable cardiac implantable devices and outcome: results from the German device registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Article
- Assessing Potential Benefit of Stroke Prophylaxis Therapy in Atrial Fibrillation and Atrial Flutter Using a Novel Competing Risk Scoring Tool.Journal of the American Heart Association · 2026Article
- Predictors and Prognostic Significance of Appropriate Implantable Cardioverter-Defibrillator Therapy in Primary Prevention Patients with Ischemic Cardiomyopathy.Journal of clinical medicine · 2026Article
- A pipeline for developing deep learning prognostic prediction models in cardiac magnetic resonance image analysis.European heart journal. Digital health · 2026Article
- A combined genomic arrhythmia propensity score delineates cumulative risk.Cell reports. Medicine · 2025Article
- Association of Risk Factors and Cardiac Outcomes in Patients With Primary Prevention of Sudden Cardiac Death: HINODE Study Sub Analysis.Journal of cardiovascular electrophysiology · 2025Article
- Ventricular Arrhythmia Risk Stratification Among Patients With Cardiac Resynchronization Therapy Devices.Circulation reports · 2025Article
- Late gadolinium enhancement imaging and sudden cardiac death.European heart journal · 2025Review
- Genotype-guided cardiac device intervention in LMNA-related cardiac conduction disorder: The need for timely genetic testing.European journal of heart failure · 2025Article
- Device Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit?CJC open · 2025Article
- Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document.European journal of heart failure · 2025Review
- Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry.ESC heart failure · 2025Article
- Survival benefit of primary prevention implantable cardioverter-defibrillator/cardiac resynchronization therapy with a defibrillator: Analysis of the Japan cardiac device treatment registry and Japanese cardiac registry of heart failure in cardiology.Journal of arrhythmia · 2025Article
- JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias.Journal of arrhythmia · 2025Article
- Prediction of sudden cardiac death using artificial intelligence: Current status and future directions.Heart rhythm · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
aimsThe benefit of prophylactic implantable cardioverter-defibrillator (ICD) is not uniform due to differences in the risk of life-threatening ventricular tachycardia (VT)/ventricular fibrillation (VF) and non-arrhythmic mortality. We aimed to develop an ICD benefit prediction score that integrates the competing risks. METHODS AND
resultsThe study population comprised all 4531 patients enrolled in the MADIT trials. Best-subsets Fine and Gray regression analysis was used to develop prognostic models for VT (≥200 b.p.m.)/VF vs. non-arrhythmic mortality (defined as death without prior sustained VT/VF). Eight predictors of VT/VF (male, age < 75 years, prior non-sustained VT, heart rate > 75 b.p.m., systolic blood pressure < 140 mmHg, ejection fraction ≤ 25%, myocardial infarction, and atrialarrhythmia) and 7 predictors of non-arrhythmic mortality (age ≥ 75 years, diabetes mellitus, body mass index < 23 kg/m2, ejection fraction ≤ 25%, New York Heart Association ≥II, ICD vs. cardiac resynchronization therapy with defibrillator, and atrial arrhythmia) were identified. The two scores were combined to create three MADIT-ICD benefit groups. In the highest benefit group, the 3-year predicted risk of VT/VF was three-fold higher than the risk of non-arrhythmic mortality (20% vs. 7%, P < 0.001). In the intermediate benefit group, the difference in the corresponding predicted risks was attenuated (15% vs. 9%, P < 0.01). In the lowest benefit group, the 3-year predicted risk of VT/VF was similar to the risk of non-arrhythmic mortality (11% vs. 12%, P = 0.41). A personalized ICD benefit score was developed based on the distribution of the two competing risks scores in the study population (https://is.gd/madit). Internal and external validation confirmed model stability.
conclusionsWe propose the novel MADIT-ICD benefit score that predicts the likelihood of prophylactic ICD benefit through personalized assessment of the risk of VT/VF weighed against the risk of non-arrhythmic mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.